Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Mei Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Acute Lung Injury, NF-kappa B, Hyperoxia. Die Arbeit nennt 40 Literaturangaben. Gefördert von: the First Affiliated Hospital of Bengbu Medical University.
Abstract (Originalsprache)
Hyperoxia‐induced acute lung injury (ALI) in neonates is driven by oxidative stress and inflammation. This study aims to evaluate the efficacy and underlying mechanisms of Relaxin‐2 (RLX‐2) in a neonatal rat model of hyperoxia‐induced ALI. Neonatal Wistar rats were exposed to 90% O 2 for one week and treated with RLX‐2 (0.5 mg/kg/day) via an osmotic pump. Methods included histopathology (hematoxylin–eosin staining), bronchoalveolar lavage fluid (BALF) analysis, Enzyme‐Linked Immunosorbent Assay (ELISA) for interleukin‐1β (IL‐1β), monocyte chemoattractant protein‐1 (MCP‐1), and tumor necrosis factor‐α (TNF‐α), oxidative stress markers [malondialdehyde (MDA) and superoxide dismutase (SOD)], and Western blotting for Toll‐like Receptor 4 (TLR4), Nuclear Factor‐kappa B (NF‐κB), and Sirtuin 1 (SIRT1). Human alveolar epithelial cells (HPAEpiCs) underwent assays using Cell Counting Kit‐8 (CCK‐8), 2′,7′‐Dichlorofluorescin diacetate (DCFH‐DA), and quantitative real‐time polymerase chain reaction (qRT‐PCR). RLX‐2 mitigated alveolar damage and inflammatory infiltration in neonatal rats with hyperoxia‐induced acute lung injury. It decreased cytokine levels, reduced MDA levels, and enhanced SOD activity, thereby alleviating oxidative stress. RLX‐2 suppressed TLR4/NF‐κB signaling by reducing p65 and Myeloid Differentiation Primary Response 88 (MyD88) expression and upregulated SIRT1. SIRT1 silencing abolished RLX‐2's effects, confirming its role in attenuating OS and inflammation. These findings demonstrated RLX‐2's efficacy in neonatal ALI via SIRT1‐dependent TLR4/NF‐κB inhibition, highlighting therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
- Department of Pediatrics, Shandong Second Medical University Affiliated Hospital, Weifang, Shandong, China.
ORCID-Profile: Aili Xuan
Förderung
- the First Affiliated Hospital of Bengbu Medical University
Zitieren
APA
Yang, M., Liu, Q., & Xuan, A. (2025). Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70140
Vancouver
Yang M, Liu Q, Xuan A. Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70140
BibTeX
@article{Yang2025,
author = {Yang, Mei and Liu, Qian and Xuan, Aili},
title = {Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70140}
}
EUVIMED